Rekha Patel, MD
Family Medicine · Endwell, NYNPI 1578598843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,379 of the $3,937 with a category attached, or 60.4%. 28 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 55.1% of the total. Reporting peaked in 2023 at $2,639 and has fallen 80.6% since, to $512 in 2025.
Across 101 payments — averaging $38.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$2K
- Novo Nordisk$302
- AbbVie$285
- Amgen$186
- Pfizer$137
- Lilly USA, LLC$125
- plus $735 from 22 others
Across 72 payments — averaging $2184.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organon$58K
- GSK$44K
- Pfizer$34K
- Vertex$22K
What the payments were for
- Travel & lodging$1,55840%
- Food & beverage$2,37960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 13 | $2,168 |
| Novo Nordisk | 18 | $302 |
| AbbVie(2 entities) | 13 | $285 |
| Amgen | 3 | $186 |
| Pfizer | 12 | $137 |
| Lilly USA, LLC | 7 | $125 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Phathom Pharmaceuticals, Inc. | 5 | $87 |
| Abbott | 4 | $59 |
| GSK | 3 | $49 |
| Edwards Lifesciences | 1 | $46 |
| Novartis | 2 | $45 |
| AstraZeneca | 2 | $42 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Corcept Therapeutics | 2 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Merck | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Si-bone, Inc. | 2 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Corium, LLC | 1 | $12 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,937 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $67,681 |
| EliquisApixaban | 31 | $31,226 |
| JardianceEmpagliflozin | 20 | $21,479 |
| FarxigaDapagliflozin Propanediol | 14 | $19,826 |
| MounjaroTirzepatide | 13 | $13,655 |
| XareltoRivaroxaban | 14 | $13,458 |
| JanuviaSitagliptin Phosphate | 13 | $12,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,480 |
| Arnuity ElliptaFluticasone Furoate | 25 | $6,526 |
| Metoprolol Succinate | 243 | $4,786 |
| Atorvastatin Calcium | 365 | $3,617 |
| Levothyroxine Sodium | 219 | $3,131 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,012 |
| Rosuvastatin Calcium | 185 | $2,864 |
| Bisoprolol Fumarate | 52 | $2,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $302 | $67,68135 claims |
| PfizerEliquis | $137 | $31,22631 claims |
| Boehringer IngelheimJardiance | $15 | $21,47920 claims |
| AstraZenecaFarxiga | $42 | $19,82614 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $49 | $17,00540 claims |
| Lilly USA, LLCMounjaro | $125 | $13,65513 claims |
| MerckJanuvia | $23 | $12,93113 claims |
| AbbVieSynthroid | $285 | $92127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Endwell
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.